FOXO4-DRI dosage chart explained: no official human dosing exists. See preclinical amounts, community protocols, safety warnings, and consult a doctor.
There is no official FOXO4-DRI dosage chart for humans. FOXO4-DRI is an experimental senolytic peptide that the FDA has not approved for human use, so no validated dosing schedule exists. The only published dosing information comes from preclinical animal studies and anecdotal community reports.
Why No Official FOXO4-DRI Dosage Chart Exists
FOXO4-DRI is a research chemical, not a medication. It is not FDA-approved for any indication, and no human clinical trials have established its safety, efficacy, or pharmacokinetics. Without that data, any dosage chart you see online is either based on animal research or on self-reported user experiences.
Researchers and regulators consistently warn that animal doses do not translate directly to humans. Body weight scaling, metabolic differences, and route of administration all change how a peptide behaves. A dose that shows senolytic activity in mice may be ineffective or dangerous in people.
Preclinical Dosing in Published Studies
The most cited FOXO4-DRI study appeared in Cell in 2017. In that mouse study, researchers administered 5 mg/kg intraperitoneally every other day for 10 days. That protocol reduced senescent cell burden and improved physical function in aged mice.
Other in vitro experiments used concentrations ranging from 10 µM to 50 µM in cell culture. Those are laboratory concentrations, not human doses. They cannot be converted into a safe injection amount for people.
| Model | Reported Dose | Route | Frequency and Duration |
|---|---|---|---|
| Aged mice (2017 Cell study) | 5 mg/kg | Intraperitoneal | Every other day for 10 days |
| Cell culture (in vitro) | 10–50 µM | Direct to medium | Single or repeated exposure |
| Human | No established dose | N/A | N/A |
No human dosage chart for FOXO4-DRI has been validated in clinical trials.
Community-Reported Protocols and Their Limitations
Online forums and bodybuilding communities sometimes share self-experimentation protocols. These reports are anecdotal, often lack purity testing, and may involve mislabeled products. They should never be treated as medical guidance.
Common community-reported ranges include:
- Subcutaneous injection: 1–5 mg per injection, 1–3 times per week.
- Intranasal: 1–2 mg per day, often split into two doses.
- Topical: Not well described; absorption is unpredictable.
Online forums often debate the ideal foxo4-dri dosage, but no consensus exists. Some users look for a foxo4-dri dosage calculator to adjust numbers by body weight, but no calculator can replace missing human safety data.
FOXO4-DRI is not a recognized performance-enhancing drug, and its use in bodybuilding is not backed by clinical research.
How FOXO4-DRI Compares to Other Peptide Dosage Charts
Unlike FOXO4-DRI, some research peptides have more established (though still non-FDA-approved) community dosage references. The table below shows typical reported ranges, but none of these are approved for human use.
| Peptide | Common Reported Range | Typical Frequency | Human Data Status |
|---|---|---|---|
| FOXO4-DRI | No established range | N/A | None |
| BPC-157 | 250–500 mcg | 1–2 times daily | Limited, not FDA-approved |
| MOTS-c | 5–10 mg per week | 2–3 times weekly | Early-stage only |
| Lipo-C | 0.5–1 mL per injection | 1–3 times weekly | Not standardized |
Many researchers also consult a bpc-157 dosage chart by weight or a mots-c dosage chart when comparing peptides. FOXO4-DRI has no equivalent because human studies are absent.
The full chemical name, foxo4 d retro inverso dri peptide, refers to a retro-inverso modification designed to resist enzymatic breakdown. That modification may change how the peptide behaves in the body, further complicating any dosage estimate.
Safety, Legal, and Practical Warnings
FOXO4-DRI is sold online as a research chemical. It is not approved for human consumption, and the FDA has not evaluated its safety. Products may be impure, mislabeled, or contaminated.
Potential risks include injection-site reactions, immune responses, and unknown long-term effects on healthy cells. Senolytic drugs can affect multiple tissues, so unintended consequences are possible.
Anyone considering FOXO4-DRI should consult a licensed healthcare professional. Self-dosing with an unapproved peptide is risky and may violate local laws.
Bottom Line on the FOXO4-DRI Dosage Chart
No official FOXO4-DRI dosage chart exists for humans. The only credible dosing information comes from a 2017 mouse study that used 5 mg/kg intraperitoneally every other day for 10 days. Community protocols vary widely and are not supported by clinical evidence.
If you are researching FOXO4-DRI, treat any dosage chart as speculative. Prioritize safety, stick to legal and approved treatments, and talk to a doctor before using any research peptide.
Frequently Asked Questions
Is there a FOXO4-DRI dosage chart for humans?
No. FOXO4-DRI is not FDA-approved, and no human clinical trials have established a safe or effective dose. Any dosage chart you find online is based on animal studies or anecdotal reports, not on validated human data.
What dose of FOXO4-DRI was used in research studies?
The most cited mouse study used 5 mg/kg intraperitoneally every other day for 10 days. Cell culture experiments used 10–50 µM, which are laboratory concentrations. These doses do not translate directly to humans.
Is FOXO4-DRI safe to use?
FOXO4-DRI is a research chemical with no human safety data. It may cause unknown side effects, and online products can be impure or mislabeled. You should consult a licensed healthcare professional before considering any unapproved peptide.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.